Periprocedural myocardial injury (PMI) is common after percutaneous coronary intervention (PCI). Periprocedural infarction (myocardial infarction type 4a) occurs after at least 10% of PCI procedures and has an impact on long-term prognosis. Measurement of biomarkers to allow assessment of PMI is an important tool for clinical and research purposes and should be routine after every PCI (troponin I or T and CK-MB). The importance of oral and intravenous antiplatelet agents and other drugs which have been proven to reduce PMI is discussed.
- HMG CoA–clopidogrel–platelet aggregation inhibitors
- coronary angioplasty
- coronary stenting
Statistics from Altmetric.com
Funding APB is partially funded by the NIHR Biomedical Research Centre Oxford.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.